Analysis of apolipoprotein E genetic variation in patients with Alzheimer disease referred to Imam Reza Clinic, Rasht, Iran, in 2015

  • Amir Reza Ghayeghran Department of Neurology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
  • Maryam Akbarshahi Mail Department of Neurology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
  • Zivar Salehi Department of Biology, School of Sciences, University of Guilan, Rasht, Iran
  • Ali Davoudi-Kiakalayeh Road Trauma Research Center, Guilan University of Medical Sciences, Rasht, Iran
Alzheimer Disease, Apolipoprotein E, Genetic Variation


Background: Alzheimer disease (AD) is a progressive neurological degenerative disorder and the most common form of dementia. There are about 100 genes linked to AD including apolipoprotein E (ApoE). This gene exists in the form of three allele polymorphisms of ε2, ε3 and ε4 and six genotypes of ε2ε3, ε2ε2, ε3ε3, ε2ε4, ε3ε4, and ε4ε4. We aimed to study the association of ApoE polymorphism with AD in Guilan province, Iran.

Methods: The study group consisted of 70 AD patients and 100 healthy individuals as a control group. All subjects were recruited from 21 March to 22 September 2015 at Imam Reza Clinic, Rasht, Iran. The genomic deoxyribonucleic acid (DNA) was extracted from peripheral blood leucocytes, and subsequently, subjects were genotyped for ApoE using tetra-primer amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). The association between the risk allele and AD was assessed using the MedCalc software.

Results: The distributions of ε3ε3, ε3ε4, ε2ε2, ε2ε4, ε4ε4 and ε2ε3 Genotypes among patients were 55.7%, 30.0%, 1.4%, 2.9%, 8.6%, 1.4% and in the controls were 79.0%, 8.0%, 0%, 1.0%, 1.0%, 11.0%, respectively. The genotype frequencies were significantly different between cases and the controls (P < 0.001). The individuals with the ε4ε4 and ε3ε4 genotypes had a greater risk for AD as compared to others; odds ratio (OR) = 12.15, 95% confidence interval (CI): 1.41-104.50, P = 0.020;
OR = 5.32, 95% CI: 2.16-13.08, P = 0.003. In addition, the ε4 allele is significantly associated with higher AD risk among the studied population (OR = 5.63, 95% CI: 2.74-11.58, P < 0.001).

Conclusion: This case-control study suggests that the subjects with ε4ε4 and ε3ε4 genotypes had an increased risk for AD in Iranian population.


1. Sadigh-Eteghad S, Talebi M, Farhoudi M. Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer`s disease. A meta-analysis. Neurosciences(Riyadh) 2012; 17(4): 321-6.
2. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: Risk, echanisms and therapy. Nat Rev Neurol 2013; 9(2): 106-18.
3. Lim AS, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA. Modification of the relationship of the apolipoprotein E epsilon4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep.JAMA Neurol 2013; 70(12): 1544-51.
4. Agarwal R, Chhillar N, Mishra VN, Tripathi CB. CSF tau and amyloid b42levels in Alzheimer's disease-Ameta-analysis. Adv Alzheimer Dis 2012;1(3): 30-44.
5. Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome- wide association study. JAMA Neurol2014; 71(11): 1394-404.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002; 297(5580):353-6.
7. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368(9533): 387-403.
8. Brickell KL, Steinbart EJ, Rumbaugh M, Payami H, Schellenberg GD, Van DeerlinV, et al. Early-onset Alzheimer disease in families with late-onset Alzheimer disease: A potential important subtype of familial Alzheimer disease. Arch Neurol 2006; 63(9): 1307-11.
9. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al.Decreased clearance of CNS beta- amyloid in Alzheimer's disease. Science2010; 330(6012): 1774.
10. Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and susceptibility genes for Alzheimer's disease: A review. Brain ResBull 2003; 61(1): 1-24.
11. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science1993; 261(5123): 921-3.
12. Sabbagh MN, Malek-Ahmadi M, Dugger BN, Lee K, Sue LI, Serrano G, et al. The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's disease. BMC Neurol 2013; 13: 44.
13. Shahsavar F, Sabooteh T, Jafarzadeh M.Distribution of ApoE polymorphisms in the Lur population. Yafte 2014; 15(5): 5-12. [In Persian].
14. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein Eimmunoreactivity in cerebral amyloid deposits and neurofibrillary tangles inAlzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541(1): 163-6.
15. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: The CERAD experience, Part XV. Neurology1996; 46(6): 1592-6.
16. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. JAMA 1997; 278(16): 1349-56.
17. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011; 3(89):89ra57.
18. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH,Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology1993; 43(8): 1467-72.
19. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41(10): 1088-93.
20. Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE- related risk of developing Alzheimer disease. Ann Neurol 2014; 75(4): 563-73.
21. Isbir T, Agachan B, Yilmaz H, Aydin M, Kara I, Eker E, et al. Apolipoprotein-E gene polymorphism and lipid profiles inAlzheimer's disease. Am J AlzheimersDis Other Demen 2001; 16(2): 77-81.
22. Zhou X, Miao H, Rausch WD, Long M, Luo X, Yu H, et al. Association betweenapolipoprotein E gene polymorphism andAlzheimer's disease in Uighur and Han populations. Psychogeriatrics 2012;12(2): 83-7.
23. Gavett BE, John SE, Gurnani AS, BussellCA, Saurman JL. The Role of Alzheimer's and Cerebrovascular Pathology in Mediating the Effects of Age, Race, and Apolipoprotein E Genotype on Dementia Severity in Pathologically-Confirmed Alzheimer's Disease. J Alzheimers Dis 2016; 49(2):531-45.
24. Mino C, Carrera C, Lopez-Cortes A, Munoz MJ, Cumbal N, Castro B, et al. Genetic polymorphisms in apolipoprotein E and glutathione peroxidase 1 genes in the Ecuadorian population affected with Alzheimer's disease. Am J Med Sci 2010;340(5): 373-7.
25. Hu CJ, Sung SM, Liu HC, Chang JG Association of apolipoprotein E genotype and intronic polymorphism of the presenilin-1 gene with Alzheimer's disease in elderly Taiwan Chinese. J Neurol Sci 1998; 157(2): 158-61.
26. Mahley RW, Rall SC, Jr. ApolipoproteinE: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1:507-37.
How to Cite
Ghayeghran AR, Akbarshahi M, Salehi Z, Davoudi-Kiakalayeh A. Analysis of apolipoprotein E genetic variation in patients with Alzheimer disease referred to Imam Reza Clinic, Rasht, Iran, in 2015. Curr J Neurol. 16(4):173-177.
Original Article(s)